SCHEMBL15637611

SCHEMBL15637611

O=C(O)c1ccnc(CNCC(=O)N2CCCC2Cc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 5/20 0.47
▸ KDM5B Q9UGL1 5/20 0.46
▸ KDM5C P41229 4/20 0.45
▸ KDM4A O75164 2/20 0.45
▸ KDM4B O94953 1/20 0.45
▸ SCD5 Q86SK9 1/20 0.44
▸ KDM6B O15054 3/20 0.42
▸ KDM5A P29375 1/20 0.42
▸ KDM2B Q8NHM5 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ DPP8 Q6V1X1 2/20 0.41
▸ DPP7 Q9UHL4 1/20 0.41
▸ TACR1 P25103 1/20 0.41
▸ PREP P48147 1/20 0.41
▸ KDM4C Q9H3R0 2/20 0.41
▸ KDM2A Q9Y2K7 2/20 0.41
▸ KDM3A Q9Y4C1 2/20 0.41
▸ ABHD6 Q9BV23 1/20 0.41
▸ DAGLA Q9Y4D2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17772478 0.87 DPP4 (0.48) DPP4SCD5KDM4EHTTDPP8
SCHEMBL16310721 0.85 HRH3 (0.46) KDM5BKDM5CKDM4AKDM6BKDM5A
SCHEMBL16291439 0.85 HRH3 (0.46) KDM5BKDM5CKDM4AKDM6BKDM5A
SCHEMBL16291521 0.85 KDM5B (0.44) DPP4KDM5BKDM5CKDM4AKDM4B
SCHEMBL19676471 0.83 KDM2B (0.42) DPP4KDM5BKDM5CKDM4AKDM6B
SCHEMBL15635924 0.77 KDM5B (0.45) KDM5BKDM5CKDM4AKDM4BKDM5A
SCHEMBL15635926 0.77 KDM5B (0.45) KDM5BKDM5CKDM4AKDM4BKDM5A
SCHEMBL16926034 0.77 KDM5B (0.46) KDM5BKDM5CKDM4AKDM4BKDM6B
SCHEMBL15636442 0.76 KDM5B (0.52) DPP4KDM5BKDM5CKDM4AKDM4B
SCHEMBL19676422 0.75 KDM4C (0.42) DPP4KDM5CDPP8PREPKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
EP-3150582-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. (US) 2017-04-05 — — EP disclosed
EP-3150582-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. (US) 2017-04-05 — — EP disclosed
US-9611219-B2 — — 2017-04-04 — — US disclosed
EP-2903968-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2016-12-07 — — EP disclosed
EP-2903968-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2016-12-07 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
EP-2903968-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2015-08-12 — — EP disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
WO-2014053491-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2014-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189787-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 DPP4 1706/4885KDM5B 34/4885KDM5C 31/4885
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 DPP4 1823/4885KDM5B 34/4885KDM5C 31/4885
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 DPP4 1706/4885KDM5B 34/4885KDM5C 31/4885
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 DPP4 1706/4885KDM5B 34/4885KDM5C 31/4885
US-10221139-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 DPP4 1706/4885KDM5B 34/4885KDM5C 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback